Delving into the Latest Updates on Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target

HIV gp140

Action

inhibitors

Mechanism

gp140 inhibitors(HIV gp140 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Janssen Vaccines & Prevention BV

Active Organization

Janssen Vaccines & Prevention BV

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.

Start Date31 Oct 2019

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

100 Clinical Results associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)

Login to view more data

100 Translational Medicine associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)

Login to view more data

100 Patents (Medical) associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)

Login to view more data

100 Deals associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	Argentina	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Brazil	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Poland	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Puerto Rico	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Peru	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Spain	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Mexico	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	Italy	Janssen Vaccines & Prevention BV	31 Oct 2019
HIV Infections	Phase 3	United States	Janssen Vaccines & Prevention BV	31 Oct 2019